Media | Contact us
SEARCH:
Bavarian Nordic

Search

Your search Jynneos returned about 116 results:

Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government

Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government BARDA has ordered 500,000 doses of liquid-frozen JYNNEOS® to be manufactured from existing bulk vaccine for delivery in 2022 Order brings the total U.S. inventory of liquid-frozen JYNNEOS to nearly 2 million doses Company upgrades financial guidance for 2022 COPENHAGEN, Denmark, June...

Bavarian Nordic Announces a New Order for JYNNEOS Smallpox Vaccine from the U.S. Government Potentially Worth USD 200 Million

Bavarian Nordic Announces a New Order for JYNNEOS Smallpox Vaccine from the U.S. Government Potentially Worth USD 200 Million The new order for up to 1.4 million liquid-frozen doses of JYNNEOS and additional vaccine bulk was placed under the existing 10-year contract awarded in 2017 USD 106 million has been secured, with the majority being revenue recognized in 2020, while the remaining option is...

Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults

Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults First FDA approved non-replicating smallpox vaccine Only FDA approved vaccine for prevention of monkeypox Company granted Priority Review Voucher Conference call and webcast tomorrow at 3:00 PM CEST COPENHAGEN, Denmark, Septemb...

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data t...

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine, MVA-BN®. This order, awarded under the existing 10-year contract ...

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.  The donation of 110,000 doses of the vaccine has been allocated to Uganda in coordination with the key partners i...

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women. The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable populations. COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced ...

Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years

Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global public health preparedness COPENHAGEN, Denmark, August 7, 20...

Bavarian Nordic Reports Strong First Half 2026 Results

Bavarian Nordic Reports Strong First Half 2026 Results COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released its financial calendar for 2027. Financial highlights Revenue in the second quarter (Q2) increased by 23% to DKK 2,034 million. Travel Health rev...

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed country in 2026 and 2027. Paul Chaplin, President & CEO of Bavarian Nordic, said: “We are p...

Bavarian Nordic Announces Interim Results for the First Three Months of 2026

Bavarian Nordic Announces Interim Results for the First Three Months of 2026 COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1,058 million, comprised of: DKK 721 million from Travel Health, an increase of 14% compared to the first ...

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines. Company upgrades full-year financial guidance COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Center for the Bi...

Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox

Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of smallpox/mpox vaccine over the next four years. Additional count...

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. Results will support filing for label extension with EMA in 2026. COPENHAGEN, Denmark, October 7, 2025 – Bavarian Nordic A...

Bavarian Nordic Announces First Half 2025 Results

Bavarian Nordic Announces First Half 2025 Results COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2025 and released its financial calendar for 2026. Revenue for the first half increased by 33% to DKK 2,998 million, reflecting a strong performance in both Travel Health and Public Prepar...

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country Recurring order from an undisclosed European country to strengthen public preparedness. Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 million in contracts in the Public Preparedness business in 2025, thus entering the targeted guidance interval for th...

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

Bavarian Nordic Announces Interim Results for the First Three Months of 2025 COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness...

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority ...

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and ...

Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines

Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak. ...

VIEW ALL